Brooke McCormick

Christina Barrington, PharmD, of Priority Health, explained the keys to leading a successful managed care organization, as well as where she predicts the industry will be in the future.

Kimberly Maxfield, PhD, of the FDA reflected upon how the FDA is uplifting the US biosimilar industry.

Prerakkumar Parikh, PharmD, of Megallen Rx Management/Prime Therapeutics, detailed the impact of formulary placement of biosimilars on cost burden along with how stakeholders can work with pharmacy benefit managers to promote biosimilar use.

Saira Jan, PharmD, MS, of Horizon Blue Cross Blue Shield of New Jersey, discussed the primary findings of their collaborative pilot program with Rutgers Cancer Institute of New Jersey and RWJ Barnabas Health, focusing on patient and provider experiences.

Chelsee Jensen, PharmD, BCPS, of Mayo Clinic, commented on the recent FDA biosimilar approvals and what they mean for the industry's future, as well as how to ensure biosimilars are accessible to all patients.

Kristen Whelchel, PharmD, CSP, of Vanderbilt University Medical Center, details what services medically integrated dispensing (MID) specialty pharmacies provide.

Jeff McIntyre, MA, of the Global Liver Institute, discussed how the delayed diagnosis of nonalcoholic steatohepatitis (NASH) affects patients and how health care and managed care professionals can help expedite diagnosis and treatment.

Kimberly Westrich, MA, of Cencora, explains how US payers' views and uses of value assessment tools have evolved.

Ben Urick, PharmD, PhD, of Prime Therapeutics, compares the value of medically integrated specialty pharmacies with that of mail order pharmacies.

The researchers explained that little is known about how primary care providers should handle atopic dermatitis (AD) cases and whether they should follow national recommendations.

Based on the researchers’ findings, gefapixant provides small benefits in cough severity, cough frequency, and cough-specific quality of life in patients with refractory or unexplained chronic coughs.

Jennifer Mathieu, MA, senior vice president of professional and government affairs of the Academy of Managed Care Pharmacy (AMCP), described what is in store for attendees during next week's AMCP Nexus meeting.

The researchers noted that their findings highlight the need to understand the challenges in delivering evidence-based care for chronic obstructive pulmonary disease (COPD).

Rajini Katipamula-Malisetti, MD, executive vice president at Minnesota Oncology, discussed what her practice is doing to continue improving patient care.

Patients with Medicare were 5.08 times more likely than patients with private insurance, and 2.81 times more likely than patients with Medicaid, to face a financial barrier to obtaining varenicline and combination nicotine replacement therapy.

Rajini Katipamula-Malisetti, MD, executive vice president of Minnesota Oncology, defined value-based cancer care and its importance.

These findings support the importance of children with atopic dermatitis (AD) receiving patch testing to consider allergic contact dermatitis as a comorbidity.

Sara Horst, MD, MPH, FACG, gave physicians tips on maintaining the personable aspects of in-person appointments during telehealth appointments and shared how digital health has helped her treat patients.

The researchers noted that their findings suggest clinicians and policy makers should encourage hepatitis C virus (HCV) treatment in those with unhealthy alcohol consumption or alcohol use disorder (AUD) rather than create barriers to it.

Rhonda Henschel, US Oncology Network's vice president of payer relations, summarized what she learned from the Minnesota Oncology IVBM and discussed new developments in the value-based cancer care space.

The chosen studies featured various methods to assess medication use initiation, implementation, and/or persistence in patients with chronic obstructive pulmonary disease (COPD).

Erin Gillaspie, MD, MPH, FACS, a faculty member of Vanderbilt University Medical Center’s Department of Thoracic Surgery, discusses new technologies making surgery on lung cancer tumors easier and expresses what currently excites her within the lung cancer space.

The researchers found that social frailty was prevalent in 36.8% of patients with chronic obstructive pulmonary disease (COPD) in the study population.

The researchers found that patients with cancer exposed to immune checkpoint inhibitors have a 1.3% risk of hepatitis B virus reactivation.

Researchers found that EczemaNet2 was more accurate and robust in terms of atopic dermatitis (AD) detection than its predecessor, EczemaNet1.

Lisa Kottschade, RN, CNP, FAPO, a nurse practitioner at Mayo Clinic, discussed immune-related adverse events and biomarkers in relation to melanoma treatment.

To reduce the global burden of respiratory diseases and tackle inequalities, the Forum of International Respiratory Studies and the American Thoracic Society suggested improving access to preventive services, inhaler therapies, and effective pneumonia vaccines.

Researchers found that approximately 17% of respondents with chronic obstructive pulmonary disease (COPD) and no lifetime history of depression developed depression during the early stages of the COVID-19 pandemic, while approximately 52% who had COPD and a history of depression experienced a recurrence of depressive symptoms.

Erin Gillaspie, MD, MPH, FACS, a faculty member of Vanderbilt University Medical Center’s Department of Thoracic Surgery, discussed the role of immunotherapies in lung cancer and how they are used.

Meredith McKean, MD, MPH, the associate director of the Sarah Cannon Research Institute's Melanoma and Skin Cancer Research Program at Tennessee Oncology, discussed new melanoma studies and treatment developments.